[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA29975B1 - Antagonistes de la neuropiline - Google Patents

Antagonistes de la neuropiline

Info

Publication number
MA29975B1
MA29975B1 MA30971A MA30971A MA29975B1 MA 29975 B1 MA29975 B1 MA 29975B1 MA 30971 A MA30971 A MA 30971A MA 30971 A MA30971 A MA 30971A MA 29975 B1 MA29975 B1 MA 29975B1
Authority
MA
Morocco
Prior art keywords
neuropilin
antagonists
variants
diagnostic
antibodies
Prior art date
Application number
MA30971A
Other languages
English (en)
Inventor
Ryan J Watts
Yan Wu
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MA29975B1 publication Critical patent/MA29975B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3023—Lung
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

LA PRÉSENTE INVENTION SE RAPPORTE À DE NOUVEAUX ANTICORPS DIRIGÉS CONTRE NRP1 ET À DES VARIANTS DE CES DERNIERS, QUI POSSÈDENT DES CARACTÉRISTIQUES STRUCTURELLES ET FONCTIONNELLES UNIQUES. L'INVENTION A ÉGALEMENT TRAIT À DES UTILISATIONS DESDITS ANTICORPS DANS DES APPLICATIONS DE RECHERCHE, DIAGNOSTIQUES ET THÉRAPEUTIQUES.
MA30971A 2005-11-08 2008-05-30 Antagonistes de la neuropiline MA29975B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US73479805P 2005-11-08 2005-11-08
US82056106P 2006-07-27 2006-07-27

Publications (1)

Publication Number Publication Date
MA29975B1 true MA29975B1 (fr) 2008-11-03

Family

ID=38023965

Family Applications (1)

Application Number Title Priority Date Filing Date
MA30971A MA29975B1 (fr) 2005-11-08 2008-05-30 Antagonistes de la neuropiline

Country Status (20)

Country Link
US (5) US7994286B2 (fr)
EP (2) EP1951758A2 (fr)
JP (2) JP5197376B2 (fr)
KR (1) KR101096359B1 (fr)
CN (2) CN102304184A (fr)
AU (1) AU2006311590B2 (fr)
BR (1) BRPI0619688A2 (fr)
CA (2) CA2892180A1 (fr)
CR (2) CR10017A (fr)
EC (1) ECSP088508A (fr)
IL (2) IL190960A (fr)
MA (1) MA29975B1 (fr)
MY (1) MY154904A (fr)
NO (1) NO20082531L (fr)
NZ (2) NZ593289A (fr)
RU (1) RU2425842C2 (fr)
SG (1) SG173408A1 (fr)
UA (2) UA96139C2 (fr)
WO (1) WO2007056470A2 (fr)
ZA (2) ZA200803811B (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060128942A1 (en) * 2003-01-31 2006-06-15 Akzo Nobel N.V. Method for protein isolation in anoxic conditions
ES2577292T3 (es) * 2005-11-07 2016-07-14 Genentech, Inc. Polipéptidos de unión con secuencias hipervariables de VH/VL diversificadas y consenso
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)
US8168181B2 (en) 2006-02-13 2012-05-01 Alethia Biotherapeutics, Inc. Methods of impairing osteoclast differentiation using antibodies that bind siglec-15
EP2438962A3 (fr) 2006-02-13 2012-07-18 Alethia Biotherapeutics Inc. Polynucléotides et séquences de polypeptides impliqués dans le procédé de remodelage des os
ES2444695T3 (es) * 2006-06-23 2014-02-26 Alethia Biotherapeutics Inc. Polinucleótidos y polipéptidos implicados en el cáncer
UA99292C2 (uk) 2007-05-17 2012-08-10 Дженентек, Інк. Антитіло, яке специфічно зв'язується з нейропіліном-2в (nrp2b)
US8877803B2 (en) * 2007-09-10 2014-11-04 Boston Biomedical, Inc. Stat3 pathway inhibitors and cancer stem cell inhibitors
WO2009050691A2 (fr) * 2007-10-19 2009-04-23 Rappaport Family Institute For Research In The Medical Sciences Compositions comprenant des sémaphorines pour le traitement de maladies associées à l'angiogenèse et leurs procédés de sélection
US9808506B2 (en) 2007-10-19 2017-11-07 Rappaport Family Institute For Research In The Medical Sciences Compositions comprising semaphorins for the treatment of cancer and methods of selection thereof
TWI580694B (zh) 2007-11-30 2017-05-01 建南德克公司 抗-ｖｅｇｆ抗體
AU2009241589B2 (en) 2008-04-29 2013-10-10 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
CN104628855A (zh) 2008-05-05 2015-05-20 诺维莫尼公司 抗il-17a/il-17f交叉反应性抗体及其使用方法
UY31800A (es) * 2008-05-05 2009-11-10 Smithkline Beckman Corp Metodo de tratamiento de cancer usando un inhibidor de cmet y axl y un inhibidor de erbb
EP2297209A4 (fr) 2008-06-03 2012-08-01 Abbott Lab Immunoglobulines à deux domaines variables et leurs utilisations
NZ589436A (en) 2008-06-03 2012-12-21 Abbott Lab Dual variable domain immunoglobulins and uses thereof
MX2010014574A (es) 2008-07-08 2011-04-27 Abbott Lab Inmunoglobulinas de dominio variable dual para prostaglandina e2 y usos de las mismas.
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
AU2009321508B2 (en) 2008-11-03 2015-03-12 Adc Therapeutics Sa Antibodies that specifically block the biological activity of a tumor antigen
WO2010054221A2 (fr) 2008-11-06 2010-05-14 The Johns Hopkins University Traitement des inflammations chroniques des voies respiratoires
MX348013B (es) 2009-05-05 2017-05-23 Novimmune Sa Anticuerpos anti il-17f y metodos de uso de los mismos.
WO2011006119A2 (fr) * 2009-07-09 2011-01-13 The Scripps Research Institute Profils d'expression génique associés à une néphropathie chronique de l'allogreffe
BR112012000735A2 (pt) * 2009-07-13 2016-11-16 Genentech Inc "métodos, kits e conjuntos de compostos"
CA2772628A1 (fr) 2009-09-01 2011-03-10 Abbott Laboratories Immunoglobulines a double domaine variable et leurs utilisations
AU2010306677B2 (en) 2009-10-15 2013-05-23 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
US20120322085A1 (en) * 2009-11-05 2012-12-20 Osaka University Therapeutic agent for autoimmune diseases or allergy, and method for screening for the therapeutic agent
ES2565208T3 (es) 2009-12-11 2016-04-01 F. Hoffmann-La Roche Ag Anticuerpos anti-VEGF-C y métodos de uso de los mismos
ES2594893T3 (es) 2009-12-16 2016-12-23 Abbvie Biotherapeutics Inc. Anticuerpos anti HER2 y sus usos
WO2011143408A1 (fr) * 2010-05-13 2011-11-17 Genentech, Inc. Utilisation d'antagonistes de la neuropiline 1 pour le traitement du cancer
WO2011153224A2 (fr) 2010-06-02 2011-12-08 Genentech, Inc. Procédés diagnostiques et compositions de traitement du cancer
WO2011159980A1 (fr) * 2010-06-18 2011-12-22 Genentech, Inc. Anticorps anti-axl, et procédés d'utilisation.
KR20120003187A (ko) * 2010-07-02 2012-01-10 한국생명공학연구원 Ｎｅｕｒｏｐｉｌｉｎ １ 유전자를 이용한 천식 진단 및 천식 치료제 스크리닝 방법
RU2571226C2 (ru) * 2010-07-09 2015-12-20 Дженентек, Инк. Антитела против нейропилина и способы их применения
WO2012018790A2 (fr) 2010-08-03 2012-02-09 Abbott Laboratories Immunoglobulines à double domaine variable et utilisations associées
AU2011293253B2 (en) 2010-08-26 2014-12-11 Abbvie Inc. Dual variable domain immunoglobulins and uses thereof
EP3176184B1 (fr) 2010-11-10 2020-02-19 F. Hoffmann-La Roche AG Anti-bace1 anticorps pour l'immunothérapie de maladies neuronales
KR101993259B1 (ko) 2011-03-31 2019-06-27 에이디씨 테라퓨틱스 에스에이 신장 결합 항원 １에 대한 항체 및 이의 항원 결합 단편
EP2522341A1 (fr) 2011-05-13 2012-11-14 Tragex Pharma Compositions pharmaceutiques comportant des inhibiteurs de la neuropiline et leur utilisation dans la prévention et/ou le traitement des troubles angiogènes et des cancers
CN104011079B (zh) * 2011-11-09 2017-06-16 Uab研究基金会 Her3抗体及其用途
AR089529A1 (es) 2011-12-30 2014-08-27 Abbvie Inc Proteinas de union especificas duales dirigidas contra il-13 y/o il-17
CA3115623A1 (en) 2012-01-09 2013-07-18 Adc Therapeutics Sa Method for treating breast cancer
SG10201610313WA (en) * 2012-06-08 2017-02-27 Janssen Biotech Inc Differentiation of human embryonic stem cells into pancreatic endocrine cells
EA201590247A1 (ru) 2012-07-19 2015-10-30 Алетиа Байотерапьютикс Инк. Антитела к siglec-15
CA2886120A1 (fr) * 2012-10-08 2014-04-17 St. Jude Children's Research Hospital Therapies fondees sur la stabilite et la fonction des lymphocytes t regulateurs par l'intermediaire d'un axe neuropiline-1:semaphorine
AU2013337775B2 (en) 2012-11-01 2017-03-30 Abbvie Inc. Anti-VEGF/DLL4 dual variable domain immunoglobulins and uses thereof
US9062108B2 (en) 2013-03-15 2015-06-23 Abbvie Inc. Dual specific binding proteins directed against IL-1 and/or IL-17
WO2014169078A2 (fr) 2013-04-09 2014-10-16 Boston Biomedical, Inc. Procédés de traitement du cancer
ITMI20131351A1 (it) * 2013-08-07 2015-02-08 Biouniversa Srl Molecole leganti il recettore di bag3 per uso terapeutico.
WO2015124588A1 (fr) * 2014-02-18 2015-08-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés et compositions pharmaceutiques pour le traitement de maladies induites par la voie de signalisation du complexe nrp-1/obr
US10443100B2 (en) 2014-05-22 2019-10-15 The Scripps Research Institute Gene expression profiles associated with sub-clinical kidney transplant rejection
US11104951B2 (en) 2014-05-22 2021-08-31 The Scripps Research Institute Molecular signatures for distinguishing liver transplant rejections or injuries
HUE054204T2 (hu) * 2014-09-05 2021-08-30 Rsem Lp Összetételek és módszerek gyulladások kezeléséhez és megelõzéséhez
JP6859259B2 (ja) 2014-11-19 2021-04-14 ジェネンテック， インコーポレイテッド ＢＡＣＥｌに対する抗体及び神経疾患免疫療法のためのその使用
JP6993228B2 (ja) 2014-11-19 2022-03-03 ジェネンテック， インコーポレイテッド 抗トランスフェリン受容体／抗ｂａｃｅ１多重特異性抗体および使用方法
JP6475835B2 (ja) * 2014-12-03 2019-02-27 サムスン ライフ パブリック ウェルフェア ファウンデーションＳａｍｓｕｎｇ Ｌｉｆｅ Ｐｕｂｌｉｃ Ｗｅｌｆａｒｅ Ｆｏｕｎｄａｔｉｏｎ ニューロピリン１（Ｎｅｕｒｏｐｉｌｉｎ １）に対する抗体およびその用途
WO2016094881A2 (fr) 2014-12-11 2016-06-16 Abbvie Inc. Protéines de liaison à lrp-8
TW201710286A (zh) 2015-06-15 2017-03-16 艾伯維有限公司 抗ｖｅｇｆ、ｐｄｇｆ及／或其受體之結合蛋白
WO2017000059A1 (fr) 2015-06-29 2017-01-05 The University Of British Columbia Agents thérapeutiques à base de protéine de fusion b1sp, procédés et utilisations
US10688178B2 (en) 2015-06-30 2020-06-23 Osaka University AntiPlexin A1 agonist antibody
CN108779172B (zh) * 2016-01-06 2022-02-08 定制药品研究株式会社 抑制vegf与nrp1结合的抗体
CN108699141B (zh) 2016-01-06 2022-06-17 定制药品研究株式会社 高亲和性抗vegf抗体
WO2017209554A2 (fr) * 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 Méthode de criblage d'anticorps anti-nrp1
US11085930B2 (en) 2016-06-03 2021-08-10 Aimed Bio Inc. Anti-NRP1 antibody screening method
WO2017209553A2 (fr) * 2016-06-03 2017-12-07 사회복지법인 삼성생명공익재단 Procédé de criblage d'anticorps à l'aide de cellules dérivées de patients
KR101985299B1 (ko) 2016-06-03 2019-09-03 삼성전자주식회사 항-c-Met/항-Nrp1 이중 특이 항체
JP6895460B2 (ja) 2016-06-03 2021-06-30 アイメッド・バイオ・インコーポレイテッド 患者由来腫瘍スフェロイドを用いた抗体スクリーニング方法
JP7106563B2 (ja) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド ナフトフラン誘導体、その調製、および使用方法
JOP20190134A1 (ar) 2016-12-23 2019-06-02 Potenza Therapeutics Inc بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
CA3062656A1 (fr) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methodes pour le traitement du cancer
CN108196071A (zh) * 2018-02-09 2018-06-22 上海市第十人民医院 肝癌血清标志物nrp1
EP3758751A4 (fr) * 2018-02-28 2021-11-17 Wuxi Biologics Ireland Limited. Anticorps monoclonal contre la lag-3 humaine, méthode permettant de le préparer, et utilisation de ce dernier
CN113226367B (zh) 2018-04-06 2025-05-06 Atyr医药公司 包括抗nrp2抗体的组合物和方法
CA3125476A1 (fr) * 2019-01-03 2020-07-09 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methodes et compositions pharmaceutiques pour ameliorer les reponses immunitaires dependantes des lymphocytes t cd8+ chez des sujets souffrant d'un cancer
CN109883932B (zh) * 2019-02-18 2021-08-10 武汉伊莱瑞特生物科技股份有限公司 流式抗体及其制备方法和滴定方法
TWI859339B (zh) 2019-09-24 2024-10-21 德商百靈佳殷格翰國際股份有限公司 抗nrp1a抗體及其用於治療眼或眼部疾病之用途
AU2020358854A1 (en) * 2019-10-03 2022-05-26 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
US20240018248A1 (en) 2020-12-02 2024-01-18 Vib Vzw An ltbr agonist in combination therapy against cancer
KR20240163751A (ko) * 2022-03-30 2024-11-19 파인트리 테라퓨틱스 인코포레이티드 Nrp1 결합 도메인을 포함하는 이중특이적 항체 및 이의 사용 방법
WO2024030341A1 (fr) * 2022-07-30 2024-02-08 Pinetree Therapeutics, Inc. Compositions pour la dégradation lysosomale ciblée et leurs procédés d'utilisation
WO2024153818A1 (fr) * 2023-01-19 2024-07-25 Theranovir Anticorps à base de peptides neuropiline-1, nouvel épitope de mise en évidence associé à la neuropiline-1 modifiée par glycosaminoglycane et ses procédés d'utilisation
EP4403578A1 (fr) * 2023-01-19 2024-07-24 Theranovir Anticorps contre un epitope d'un neuropiline-1-peptide modifiée par glycosaminoglycane et procédés d'utilisation de celui-ci
CN117164711B (zh) * 2023-09-28 2024-01-30 北京凯祥弘康生物科技有限公司 一种抗神经纤维丝轻链蛋白的抗体

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US550362A (en) * 1895-11-26 crosby
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4275149A (en) 1978-11-24 1981-06-23 Syva Company Macromolecular environment control in specific receptor assays
US4318980A (en) 1978-04-10 1982-03-09 Miles Laboratories, Inc. Heterogenous specific binding assay employing a cycling reactant as label
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4419446A (en) 1980-12-31 1983-12-06 The United States Of America As Represented By The Department Of Health And Human Services Recombinant DNA process utilizing a papilloma virus DNA as a vector
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
US4601978A (en) 1982-11-24 1986-07-22 The Regents Of The University Of California Mammalian metallothionein promoter system
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4675187A (en) 1983-05-16 1987-06-23 Bristol-Myers Company BBM-1675, a new antibiotic complex
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
US4965199A (en) 1984-04-20 1990-10-23 Genentech, Inc. Preparation of functional human factor VIII in mammalian cells using methotrexate based selection
US4879231A (en) 1984-10-30 1989-11-07 Phillips Petroleum Company Transformation of yeasts of the genus pichia
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1989006692A1 (fr) 1988-01-12 1989-07-27 Genentech, Inc. Procede de traitement de cellules tumorales par inhibition de la fonction receptrice du facteur de croissance
DE68925971T2 (de) 1988-09-23 1996-09-05 Cetus Oncology Corp Zellenzuchtmedium für erhöhtes zellenwachstum, zur erhöhung der langlebigkeit und expression der produkte
US5750373A (en) 1990-12-03 1998-05-12 Genentech, Inc. Enrichment method for variant proteins having altered binding properties, M13 phagemids, and growth hormone variants
KR0184860B1 (ko) 1988-11-11 1999-04-01 메디칼 리써어치 카운실 단일영역 리간드와 이를 포함하는 수용체 및 이들의 제조방법과 이용(법)
FR2646437B1 (fr) 1989-04-28 1991-08-30 Transgene Sa Nouvelles sequences d'adn, leur application en tant que sequence codant pour un peptide signal pour la secretion de proteines matures par des levures recombinantes, cassettes d'expression, levures transformees et procede de preparation de proteines correspondant
EP0402226A1 (fr) 1989-06-06 1990-12-12 Institut National De La Recherche Agronomique Vecteurs de transformation de la levure yarrowia
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
JP3672306B2 (ja) 1991-04-10 2005-07-20 ザ スクリップス リサーチ インスティテュート ファージミドを使用するヘテロ二量体受容体ライブラリー
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
AU3178993A (en) 1991-11-25 1993-06-28 Enzon, Inc. Multivalent antigen-binding proteins
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
TW225528B (fr) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
CN1173991C (zh) 1992-11-13 2004-11-03 马克斯普朗克科学促进协会 作为血管内皮生长因子受体的f1k-1
DE122004000036I1 (de) 1992-11-13 2005-07-07 Biogen Idec Inc Therapeutische Verwendung von chimerischen und markierten Antik¦rper gegen menschlichen B Lymphozyt beschr{nkter Differenzierung antigen f}r die Behandlung von B-Zell-Lymphoma.
DK0672142T3 (da) 1992-12-04 2001-06-18 Medical Res Council Multivalente og multispecifikke bindingsproteiner samt fremstilling og anvendelse af disse
US5635388A (en) 1994-04-04 1997-06-03 Genentech, Inc. Agonist antibodies against the flk2/flt3 receptor and uses thereof
GB9410534D0 (en) 1994-05-26 1994-07-13 Lynxvale Ltd Improvements in or relating to growth factor inhibitors
IL117645A (en) 1995-03-30 2005-08-31 Genentech Inc Vascular endothelial cell growth factor antagonists for use as medicaments in the treatment of age-related macular degeneration
US5874562A (en) 1995-06-07 1999-02-23 Progenitor, Inc. Nucleic acid encoding developmentally-regulated endothelial cell locus-1
US6020473A (en) 1995-08-25 2000-02-01 Genentech, Inc. Nucleic acids encoding variants of vascular endothelial cell growth factor
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
ES2236634T3 (es) 1997-04-07 2005-07-16 Genentech, Inc. Anticuerpos anti-vegf.
CN101210051B (zh) 1997-04-07 2012-12-26 基因技术股份有限公司 抗-血管内皮生长因子的抗体
ES2292204T3 (es) 1997-06-18 2008-03-01 MERCK & CO., INC. (A NEW JERSEY CORP.) Receptor de tipo tirosina cinasa humano, kdr.
EP0892047A3 (fr) * 1997-07-09 2000-03-08 Hoechst Marion Roussel Deutschland GmbH Semaphorine L humaine et murine
CA2313607A1 (fr) 1997-12-09 1999-06-17 Children's Medical Center Corporation Fonction et utilisation de l'antagoniste du recepteur de la neuropiline
JP4312955B2 (ja) 1997-12-09 2009-08-12 チルドレンズ・メディカル・センター・コーポレイション 血管内皮増殖因子のペプチドアンタゴニスト
US6777534B1 (en) 1997-12-09 2004-08-17 Children's Medical Center Corporation Peptide antagonists of vascular endothelial growth factor
EP1037981A1 (fr) 1997-12-09 2000-09-27 Children's Medical Center Corporation Inhibiteurs solubles du facteur de croissance de l'endothelium vasculaire et leurs utilisations
GB9800569D0 (en) 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
AR034118A1 (es) 2000-02-15 2004-02-04 Sugen Inc Compuestos de 2-indolinonas sustituidas con pirroles inhibidoras de proteinquinasas; sus composiciones farmaceuticas e intermediarios de sintesis
NZ556507A (en) 2002-06-03 2010-03-26 Genentech Inc Synthetic antibody phage libraries
EP1439192A1 (fr) * 2003-01-15 2004-07-21 Xerion Pharmaceuticals AG Inhibiteurs de neuropilin-1
US6956123B2 (en) * 2003-03-17 2005-10-18 Natural Pharmaccuticals, Inc. Purification of taxanes and taxane mixtures using polyethyleneimine-bonded resins
KR101225463B1 (ko) * 2003-11-07 2013-01-24 임뮤넥스 코포레이션 인터류킨-4 수용체에 결합하는 항체
US7563443B2 (en) * 2004-09-17 2009-07-21 Domantis Limited Monovalent anti-CD40L antibody polypeptides and compositions thereof
UA96139C2 (uk) 2005-11-08 2011-10-10 Дженентек, Інк. Антитіло до нейропіліну-1 (nrp1)

Also Published As

Publication number Publication date
KR20080068105A (ko) 2008-07-22
JP2011256183A (ja) 2011-12-22
BRPI0619688A2 (pt) 2011-10-11
CA2629028A1 (fr) 2007-05-18
US8795660B2 (en) 2014-08-05
RU2425842C2 (ru) 2011-08-10
IL190960A0 (en) 2011-08-01
ZA200903718B (en) 2011-03-30
ZA200803811B (en) 2009-08-26
IL222922A0 (en) 2012-12-31
US20120245330A1 (en) 2012-09-27
ECSP088508A (es) 2008-07-30
UA96139C2 (uk) 2011-10-10
RU2008122710A (ru) 2009-12-20
CR10017A (es) 2008-11-06
CN101326196A (zh) 2008-12-17
WO2007056470A3 (fr) 2007-08-09
US20110256146A1 (en) 2011-10-20
EP2570434A3 (fr) 2013-04-17
EP2570434A2 (fr) 2013-03-20
MY154904A (en) 2015-08-28
US8378080B2 (en) 2013-02-19
NZ593289A (en) 2012-12-21
US20130115214A1 (en) 2013-05-09
NO20082531L (no) 2008-06-09
KR101096359B1 (ko) 2011-12-20
NZ567514A (en) 2011-08-26
SG173408A1 (en) 2011-08-29
UA98585C2 (uk) 2012-05-25
WO2007056470A2 (fr) 2007-05-18
CN102304184A (zh) 2012-01-04
US7994286B2 (en) 2011-08-09
CA2892180A1 (fr) 2007-05-18
JP5197376B2 (ja) 2013-05-15
JP2009514972A (ja) 2009-04-09
IL222922A (en) 2015-07-30
AU2006311590B2 (en) 2011-09-08
EP1951758A2 (fr) 2008-08-06
US8211429B2 (en) 2012-07-03
CR20140518A (es) 2015-01-09
IL190960A (en) 2015-01-29
US20160304613A1 (en) 2016-10-20
CN101326196B (zh) 2015-06-24
US20080213268A1 (en) 2008-09-04
AU2006311590A1 (en) 2007-05-18

Similar Documents

Publication Publication Date Title
MA29975B1 (fr) Antagonistes de la neuropiline
RS50660B (sr) Dihidrotetrabenazini i farmaceutske kompozicije koje ih sadrže
EA200800952A1 (ru) Конъюгаты антитело-лекарство и способы применения
MA31231B1 (fr) Anticorps anti-robo4 et utilisations de ceux-ci
EP1920065A4 (fr) Anticorps anti-alpha v beta 6 et leurs utilisations
FR2888850B1 (fr) Nouveaux anticorps anti-igf-ir et leurs applications
MA29014B1 (fr) Formulations d'anticorps
MA30945B1 (fr) Anticorps anti-tat226 et immunoconjugués
ATE414725T1 (de) Amphotere ethylmethacrylat-copolymere und deren verwendung
EP1542721A4 (fr) Anticorps "s" modifies
EP1844157A4 (fr) Stratégies pour élaborer des médicaments qui ciblent la famille d'enzymes sir2
EP1877795A4 (fr) Profilage diagnostique d'anticorps seriques
FR2924118B1 (fr) Fragments d'anticorps inhibiteurs de la proteine nef du vih.
FR2891314B1 (fr) Bras d'injecteur anti-cokefaction.
EA200701172A1 (ru) 2-алкокси-3,4,5-тригидроксиалкиламиды, их получение, композиции, их содержащие, и применение
ITMI20050265U1 (it) Indumento intimo ovvero capo d'abbigliamento integrante tale indumento intimo
ITMI20040124A1 (it) Macrolidi ad attivita' antiinfiammatoria
ATE399532T1 (de) Medizinische seife
FR2920770B1 (fr) Nouveaux derives de phenylurees, inhibiteurs de l'enzyme soat-1, compositions pharmaceutiques et cosmetiques les contenant
EA200400393A1 (ru) Антитела против каспазы-8, их получение и применение
MA30465B1 (fr) Compose peptidique dote d'une activite biologique, sa preparation et ses applications.
BRPI0410638A (pt) derivados de azitromicina
TR200600020U (tr) Üretim montajı kolay bir mobilya bağlantı elemanı
HN2002000177A (es) 2-tio-3,5-diciano-4-fenil-6-aminopiridinas substituidas y su uso.
ECSP003412A (es) Derivados de 3- amino -3-arilpropan - 1 - ol, su preparacion y su uso